Tymlos® (abaloparatide) – New indication
December 20, 2022 - Radius Health announced the FDA approval of Tymlos (abaloparatide), to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.
Top